Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus DEXONE 1 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus DEXONE 1 5.
BREO ELLIPTA vs DEXONE 1.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1.5 mg orally once daily
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid